(BBWI) Bath & Body Works - Ratings and Ratios
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US0708301041
Fragrance, Candles, Soap, Lotion, Sanitizer
Dividends
| Dividend Yield | 3.99% |
| Yield on Cost 5y | 3.76% |
| Yield CAGR 5y | 27.79% |
| Payout Consistency | 82.7% |
| Payout Ratio | 24.2% |
| Risk via 10d forecast | |
|---|---|
| Volatility | 73.5% |
| Value at Risk 5%th | 112% |
| Relative Tail Risk | -7.43% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.87 |
| Alpha | -66.34 |
| CAGR/Max DD | -0.27 |
| Character TTM | |
|---|---|
| Hurst Exponent | |
| Beta | 1.544 |
| Beta Downside | 1.663 |
| Drawdowns 3y | |
|---|---|
| Max DD | 69.98% |
| Mean DD | 27.78% |
| Median DD | 27.86% |
Description: BBWI Bath & Body Works November 06, 2025
Bath & Body Works, Inc. (NYSE: BBWI) is a specialty retailer focused on home fragrance, personal care, and related products, offering items such as 3-wick candles, diffusers, hand soaps, lotions, and body creams under the Bath & Body Works, White Barn, and other brand names.
The company sells its merchandise through a network of over 1,800 retail stores and a growing e-commerce platform in the United States and Canada, while international expansion is pursued via franchise, licensing, and wholesale partnerships.
Key recent metrics: FY 2023 revenue was approximately $3.5 billion, with same-store sales (SSS) up 4.2% YoY and e-commerce sales accelerating to roughly 15% of total revenue, reflecting strong digital adoption. The sector is highly sensitive to consumer discretionary spending and inflation trends, making household disposable income and CPI movements critical drivers of BBWI’s top-line performance.
For a deeper, data-driven dive into BBWI’s valuation assumptions and scenario analysis, you may find the research tools on ValueRay useful.
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income (699.0m TTM) > 0 and > 6% of Revenue (6% = 441.2m TTM) |
| FCFTA 0.19 (>2.0%) and ΔFCFTA 6.06pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 4.46% (prev 1.95%; Δ 2.51pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.24 (>3.0%) and CFO 1.18b > Net Income 699.0m (YES >=105%, WARN >=100%) |
| Net Debt (4.74b) to EBITDA (1.50b) ratio: 3.16 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.21 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (211.6m) change vs 12m ago -3.37% (target <= -2.0% for YES) |
| Gross Margin 44.13% (prev 43.97%; Δ 0.15pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 147.5% (prev 149.1%; Δ -1.64pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 4.38 (EBITDA TTM 1.50b / Interest Expense TTM 283.0m) >= 6 (WARN >= 3) |
Altman Z'' 0.70
| (A) 0.07 = (Total Current Assets 1.88b - Total Current Liabilities 1.55b) / Total Assets 4.99b |
| (B) -0.35 = Retained Earnings (Balance) -1.75b / Total Assets 4.99b |
| (C) 0.25 = EBIT TTM 1.24b / Avg Total Assets 4.99b |
| (D) -0.24 = Book Value of Equity -1.57b / Total Liabilities 6.58b |
| Total Rating: 0.70 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 61.84
| 1. Piotroski 6.0pt |
| 2. FCF Yield 10.79% |
| 3. FCF Margin 12.86% |
| 4. Debt/Equity -3.13 |
| 5. Debt/Ebitda 3.16 |
| 6. ROIC - WACC (= 32.91)% |
| 7. RoE -46.79% |
| 8. Rev. Trend -20.31% |
| 9. EPS Trend -27.55% |
What is the price of BBWI shares?
As of December 14, 2025, the stock is trading at USD 20.05 with a total of 4,877,633 shares traded.
Over the past week, the price has changed by +6.48%, over one month by -9.34%, over three months by -25.37% and over the past year by -44.64%.
Over the past week, the price has changed by +6.48%, over one month by -9.34%, over three months by -25.37% and over the past year by -44.64%.
Is BBWI a buy, sell or hold?
Bath & Body Works has received a consensus analysts rating of 3.85.
Therefore, it is recommended to buy BBWI.
- Strong Buy: 7
- Buy: 4
- Hold: 8
- Sell: 1
- Strong Sell: 0
What are the forecasts/targets for the BBWI price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 24.3 | 21% |
| Analysts Target Price | 24.3 | 21% |
| ValueRay Target Price | 18.3 | -8.6% |
BBWI Fundamental Data Overview December 12, 2025
Market Cap USD = 4.03b (4.03b USD * 1.0 USD.USD)
P/E Trailing = 6.0464
P/E Forward = 5.3447
P/S = 0.5476
P/EG = 0.7942
Beta = 1.474
Revenue TTM = 7.35b USD
EBIT TTM = 1.24b USD
EBITDA TTM = 1.50b USD
Long Term Debt = 3.89b USD (from longTermDebt, last quarter)
Short Term Debt = 193.0m USD (from shortTermDebt, last quarter)
Debt = 4.98b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 4.74b USD (from netDebt column, last quarter)
Enterprise Value = 8.77b USD (4.03b + Debt 4.98b - CCE 236.0m)
Interest Coverage Ratio = 4.38 (Ebit TTM 1.24b / Interest Expense TTM 283.0m)
FCF Yield = 10.79% (FCF TTM 946.0m / Enterprise Value 8.77b)
FCF Margin = 12.86% (FCF TTM 946.0m / Revenue TTM 7.35b)
Net Margin = 9.51% (Net Income TTM 699.0m / Revenue TTM 7.35b)
Gross Margin = 44.13% ((Revenue TTM 7.35b - Cost of Revenue TTM 4.11b) / Revenue TTM)
Gross Margin QoQ = 41.28% (prev 41.32%)
Tobins Q-Ratio = 1.76 (Enterprise Value 8.77b / Total Assets 4.99b)
Interest Expense / Debt = 1.37% (Interest Expense 68.0m / Debt 4.98b)
Taxrate = 25.24% (26.0m / 103.0m)
NOPAT = 926.2m (EBIT 1.24b * (1 - 25.24%))
Current Ratio = 1.21 (Total Current Assets 1.88b / Total Current Liabilities 1.55b)
Debt / Equity = -3.13 (negative equity) (Debt 4.98b / totalStockholderEquity, last quarter -1.59b)
Debt / EBITDA = 3.16 (Net Debt 4.74b / EBITDA 1.50b)
Debt / FCF = 5.01 (Net Debt 4.74b / FCF TTM 946.0m)
Total Stockholder Equity = -1.49b (last 4 quarters mean from totalStockholderEquity)
RoA = 14.01% (Net Income 699.0m / Total Assets 4.99b)
RoE = -46.79% (negative equity) (Net Income TTM 699.0m / Total Stockholder Equity -1.49b)
RoCE = 51.71% (EBIT 1.24b / Capital Employed (Equity -1.49b + L.T.Debt 3.89b))
RoIC = 38.71% (NOPAT 926.2m / Invested Capital 2.39b)
WACC = 5.80% (E(4.03b)/V(9.01b) * Re(11.71%) + D(4.98b)/V(9.01b) * Rd(1.37%) * (1-Tc(0.25)))
Discount Rate = 11.71% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -3.66%
[DCF Debug] Terminal Value 64.99% ; FCFE base≈824.8m ; Y1≈783.4m ; Y5≈749.7m
Fair Price DCF = 38.30 (DCF Value 7.84b / Shares Outstanding 204.7m; 5y FCF grow -6.55% → 3.0% )
EPS Correlation: -27.55 | EPS CAGR: -39.47% | SUE: -0.70 | # QB: 0
Revenue Correlation: -20.31 | Revenue CAGR: -15.73% | SUE: -1.32 | # QB: 0
EPS next Quarter (2026-04-30): EPS=0.33 | Chg30d=-0.177 | Revisions Net=-9 | Analysts=12
EPS next Year (2027-01-31): EPS=2.75 | Chg30d=-0.976 | Revisions Net=-13 | Growth EPS=-5.3% | Growth Revenue=-1.9%
P/E Trailing = 6.0464
P/E Forward = 5.3447
P/S = 0.5476
P/EG = 0.7942
Beta = 1.474
Revenue TTM = 7.35b USD
EBIT TTM = 1.24b USD
EBITDA TTM = 1.50b USD
Long Term Debt = 3.89b USD (from longTermDebt, last quarter)
Short Term Debt = 193.0m USD (from shortTermDebt, last quarter)
Debt = 4.98b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 4.74b USD (from netDebt column, last quarter)
Enterprise Value = 8.77b USD (4.03b + Debt 4.98b - CCE 236.0m)
Interest Coverage Ratio = 4.38 (Ebit TTM 1.24b / Interest Expense TTM 283.0m)
FCF Yield = 10.79% (FCF TTM 946.0m / Enterprise Value 8.77b)
FCF Margin = 12.86% (FCF TTM 946.0m / Revenue TTM 7.35b)
Net Margin = 9.51% (Net Income TTM 699.0m / Revenue TTM 7.35b)
Gross Margin = 44.13% ((Revenue TTM 7.35b - Cost of Revenue TTM 4.11b) / Revenue TTM)
Gross Margin QoQ = 41.28% (prev 41.32%)
Tobins Q-Ratio = 1.76 (Enterprise Value 8.77b / Total Assets 4.99b)
Interest Expense / Debt = 1.37% (Interest Expense 68.0m / Debt 4.98b)
Taxrate = 25.24% (26.0m / 103.0m)
NOPAT = 926.2m (EBIT 1.24b * (1 - 25.24%))
Current Ratio = 1.21 (Total Current Assets 1.88b / Total Current Liabilities 1.55b)
Debt / Equity = -3.13 (negative equity) (Debt 4.98b / totalStockholderEquity, last quarter -1.59b)
Debt / EBITDA = 3.16 (Net Debt 4.74b / EBITDA 1.50b)
Debt / FCF = 5.01 (Net Debt 4.74b / FCF TTM 946.0m)
Total Stockholder Equity = -1.49b (last 4 quarters mean from totalStockholderEquity)
RoA = 14.01% (Net Income 699.0m / Total Assets 4.99b)
RoE = -46.79% (negative equity) (Net Income TTM 699.0m / Total Stockholder Equity -1.49b)
RoCE = 51.71% (EBIT 1.24b / Capital Employed (Equity -1.49b + L.T.Debt 3.89b))
RoIC = 38.71% (NOPAT 926.2m / Invested Capital 2.39b)
WACC = 5.80% (E(4.03b)/V(9.01b) * Re(11.71%) + D(4.98b)/V(9.01b) * Rd(1.37%) * (1-Tc(0.25)))
Discount Rate = 11.71% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -3.66%
[DCF Debug] Terminal Value 64.99% ; FCFE base≈824.8m ; Y1≈783.4m ; Y5≈749.7m
Fair Price DCF = 38.30 (DCF Value 7.84b / Shares Outstanding 204.7m; 5y FCF grow -6.55% → 3.0% )
EPS Correlation: -27.55 | EPS CAGR: -39.47% | SUE: -0.70 | # QB: 0
Revenue Correlation: -20.31 | Revenue CAGR: -15.73% | SUE: -1.32 | # QB: 0
EPS next Quarter (2026-04-30): EPS=0.33 | Chg30d=-0.177 | Revisions Net=-9 | Analysts=12
EPS next Year (2027-01-31): EPS=2.75 | Chg30d=-0.976 | Revisions Net=-13 | Growth EPS=-5.3% | Growth Revenue=-1.9%
Additional Sources for BBWI Stock
News:
Wall Street Journal |
Benzinga |
Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle